



PROGRAM

16th Women's Health Congress

Thursday January 16, 2020

Wednesday January 15, 2020

- Board Meetings
 - General Assemblies
 - SSRM – Workshop Fertiforum + SAPGG
 - SWICE Scientific Meeting
-



CHUV LAUSANNE

Auditoire Mathias Mayor

Rue du Bugnon 46 – 1011 LAUSANNE


Dear colleagues,

We are delighted to welcome you in Lausanne for the 16th Women's Health Congress!

Like every year, the Swiss Society of Reproductive Medicine and the Swiss Society of Menopause are meeting for their general assembly and board meeting as well as to discuss important topics. The FIVNAT member meeting is also an important part of the Congress.

This year we will focus on the potential risks of electromagnetic radiation. The benefits and the risks of the recently modified Swiss law regulating reproductive medicine will also be discussed. The challenge and the solutions regarding healthy aging will be presented during two separate sessions. For the keynote lecture, we will have the privilege to listen to Dr Ben Davies from the University of Oxford who will give a lecture about the controversial topic of germline editing.


We are looking forward to seeing all of you,



Prof. Petra Stute
President SMS



Dr. Nicolas Vulliemoz
Congress President



Prof. Michael von Wolff
President SSRM

GENERAL INFORMATION

Congress venue

University Hospital, CHUV – Auditoire Mathias Mayor
Rue du Bugnon 46, 1011 Lausanne

Congress President & Local Organisation

Dr. med. Nicolas Vulliemoz (CHUV), Lausanne
Head of the Reproductive Medicine Unit

President SMS Swiss Menopause Society

Professor Petra Stute
Gynaecological endocrinology and reproductive medicine
Frauenklinik / Inselspital Bern
Friedbühlstrasse 19
3010 Bern

President SSRM Swiss Society of Reproductive Medicine

Professor Michael von Wolff
Gynaecological endocrinology and reproductive medicine
Frauenklinik / Inselspital Bern
Friedbühlstrasse 19
3010 Bern

Exhibition

An industrial exhibition is organised at the venue and will be open throughout the congress. Coffee breaks and lunch will take place within the exhibition. We would recommend a visit to the each booth where new services and products are displayed, and highly thank the participating exhibitors for their support. The coffee breaks and lunch on January 16th will be served in the exhibition.

Language

Presentations are held in English or mother language of the speaker.
Slides are configured in English.
Discussion in mother language or in English.
No simultaneous translation.

Credits

Swiss Society of Obstetrics and Gynaecology (SSGO)

7 Credits

Swiss Academy of Psychomatic and Psychosocial Medicine (SAPPM)

15.01.2020 3 Credits 16.01.2020 2.5 Credits

The confirmation of participation will be sent to you electronically as a pdf file within 5 days of the end of the congress.

GENERAL INFORMATION

Congress Secretariat

meeting-com Congress Organisation
Rue des Pâquis 1 ■ CP 100
1033 Cheseaux-sur-Lausanne
T +41 (0)21 312 92 61 ■ F +41 (0)21 312 92 63
anna.forster@meeting-com.ch

Online Registration

www.meeting-com.ch

Registration Fees

Congress Thursday 16.01.2020

Members SSRM, SMS
NON-Members
Residents/nurses/family planning

Early bird
until 30.11.2019

☐ CHF 230.00
☐ CHF 280.00
☐ CHF 160.00

Late & onsite fee
from 01.12.2019

☐ CHF 260.00
☐ CHF 300.00
☐ CHF 190.00

Including

Certificate of attendance, access to the scientific sessions and the exhibition, link for the presentations after the congress, coffee-breaks and lunch on January 16, 2020.

SSRM-Workshop Fertiforum & SAPGG

Wednesday January 15, 2020 – limited places

Participation ☐ CHF 80.00

Congress documents & badge

The participants will get their congress documents at the welcome desk during the opening hours. Only participants with a badge will be allowed to attend the conferences and visit the exhibition. The badge is to be worn throughout the whole congress.

Payment

Upon registration a confirmation is sent by email together with the relevant invoice and the banking details for the payment. Payment by credit card is also possible.

Cancellation & conditions

In case of cancellation 30 days prior to the event, the refund of the amount paid will be done net of CHF 60.00 for administrative costs. Thereafter no refund possible. Any registration made within the «early bird» time must be paid during this period. If not the case, the invoice is automatically updated to the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.


Hotel Booking

Hotel propositions on www.lausanne-tourisme.ch.
The congress office is also at disposal for any help required.

GENERAL INFORMATION

Access

If possible avoid coming by car, for the parking is quickly full and expensive.



Arrival

- By car Exit motorway « Lausanne-Vennes / Hôpitaux »
Take the « Route de Berne » at the traffic lights
Follow the CHUV boarding & « P-CHUV » for parking
The auditorium is at the entrance on your left, at the exit of the parking
- By metro (M2) From Lausanne station in direction of Croisettes / Sallaz
Exit at « CHUV » station
The CHUV is on your left. The auditorium will be boarded accordingly.

women's
health

Marysa®

2,5mg de tibolone



- Pour le traitement des symptômes de la carence en œstrogènes consécutive à la ménopause
- Pour la prévention de l'ostéoporose après la ménopause
- Le générique du tibolone le plus avantageux*

ADMIS PAR LES CAISSES

 **GEDEON RICHTER**

Marysa®: Comprimé de 2,5 mg de tibolone (tibolone). 1. 1.) Traitement des symptômes de la carence en œstrogènes consécutive à la ménopause naturelle ou artificielle (datant d'au moins un an). 2.) Pour prévenir ou retarder l'apparition de l'ostéoporose induite par une carence en œstrogènes chez les femmes ménopausées encaissant un risque élevé de fractures, chez lesquelles un traitement par d'autres médicaments autorisés pour la prévention de l'ostéoporose ne peut pas être envisagé ou chez les femmes qui souffrent en même temps de symptômes de carence en œstrogènes qui requièrent un traitement. La décision de prescrire Marysa doit, chez toutes les femmes, être précédée d'un examen individuel en ce qui concerne le risque global; le risque d'accident vasculaire cérébral doit être pris en considération, notamment chez des femmes de plus de 60 ans. Dr. 1 comp./jour. Le traitement ne doit pas être complété par un progestatif supplémentaire. C: présence ou antécédents de cancer du sein, ou suspicion d'un tel cancer, présence ou suspicion de tumeurs hormono-dépendantes, hyperplasie de l'endomètre non traitée, hémorragies vaginales d'origine indéterminée, présence ou antécédents d'événements thromboemboliques veineux ou artériels, maladies thrombotiques, maladie hépatique aiguë ou antécédents de maladie hépatique, tant que les paramètres hépatiques sont augmentés, porphyrie, grossesse, allaitement, hypersensibilité connue à l'un des composants. MG: toute hémorragie vaginale anormale nécessite une exploration avant le début d'un traitement notamment pour exclure des causes malignes. En cas de saignements intermittents ou spotting pendant le traitement ou après la fin du traitement un examen gynécologique doit être effectué afin d'exclure des altérations malignes de l'endomètre. Le traitement doit être arrêté immédiatement en cas de survenue ou de suspicion d'une maladie thromboembolique veineuse ou artérielle, de la première apparition de céphalées migraineuses ou céphalées répétées, inhabituellement intenses, de perte soudaine de la vision, de trouble soudain de l'audition, d'élévation significative de la pression artérielle, d'ictère, d'hépatite ou de détérioration de la fonction hépatique. Une surveillance particulière doit être assurée en cas de facteurs de risque de tumeurs œstrogène-dépendantes chez des parents du premier degré, d'antécédents personnels ou familiaux d'hyperplasie de l'endomètre, de kystes ou d'endométriose, de facteurs de risque d'affections thromboemboliques, hypertension, migraine ou (fortes) céphalées, diabète sucré avec ou sans atteinte vasculaire, affections hépatiques ou biliaires, lupus érythémateux disséminé, épilepsie, asthme, otosclérose, maladies tumorales, pathologies cardiaques ou rénales, hypertéroglycémie, en cas d'administration concomitante de l'association de principes actifs ombitasivir/partirévir/rilovir avec ou sans darunavir. Marysa n'a aucun effet contraceptif. (A: les inducteurs du CYP3A4, les inhibiteurs, les antagonistes, des interactions sont possibles avec les substrats du CYP3A4. G/A: continué. Et: prise de poids, douleurs abdominales, hypertrichose, hypertrophie de l'endomètre ou épaississement de l'endomètre à l'échographie, douleurs mammaires, prurit génital, vaginites, candidose génitale, hémorragies vaginales (égale à spotting), douleurs pelviennes, modifications du frottis cervical (y compris dysplasie), leucorrhée, vulvovaginite. Liste B. Mise à jour Mai 2017. Plus d'information sur www.swissmedinfo.ch. Titulaire de l'autorisation: Gedeon Richter (Suisse) SA, Gewerbestrasse 5, 6330 Cham.

* selon www.listedesspecialites.ch / 04/2019

Wednesday, January 15, 2020

08.00	Welcome of participants	FOYER
08.30-11.30	WORKSHOP FERTIFORUM & SAPGG Workshop language is French, translations in German or English if necessary Chair: Dr. Anna Raggi, Fertiluisse Basel and Olten Quel accompagnement psychologique proposer aux femmes lors de fausses-couches à répétition: une option ou un usage courant de soin Enquête sur les pratiques dans les centres de PMA en Suisse: que dit la littérature? Mrs Véronique Eckert, SIPE Sion; Mrs Fabienne Coquillat, Unité Psycho-Sociale CHUV-DFME, Lausanne	SEMINAR 3
10.00-10.30	Coffee break	FOYER
11.30-12.15	Board Meeting SSRM	SEMINAR 4
12.00-13.00	Snack	FOYER
12.30-14.00	FIVNAT Member Meeting	MATHIAS MAYOR
14.15-15.15	General Assembly SSRM	MATHIAS MAYOR
15.15-15.45	Coffee break	FOYER
15.45-17.15	Board Meeting SMS	SEMINAR 4
15.45-17.15	SWICE Scientific Meeting LAB meets Clinic Chairs: Mrs Ana Martins, Basel; Dr. Fabien Murisier, Lausanne	MATHIAS MAYOR
15.45-16.25	Ovarian stimulation and embryo selection strategies: a balance between efficacy and safety Prof. Christina Bergh, Göteborg (SE)	
16.25-16.50	Technique of Trophectoderm biopsy and aneuploidy rates. Lab and clinical Management Dr. Mary Fahy-Deshe, Zürich	
16.50-17.15	Modified natural cycles for poor responders Dr. Célia Targa, Lausanne and Geneva	
17.15	End of session	
17.15-18.15	General Assembly SMS	SEMINAR 4
17.30-18.30	SYMPOSIUM sponsored by CooperSurgical Reproductive Genetics: meaningful innovations and clinical case reports	MATHIAS MAYOR

Thursday, January 16, 2020

From 08.00	Registration	FOYER
08.50	Welcome address Dr. Nicolas Vulliemoz, Lausanne	MATHIAS MAYOR
09.00-10.00	PLENARY 1 RISKS AND SAFETY Chairs: Prof. Michael von Wolff, Bern; Dr. Nicolas Vulliemoz, Lausanne	MATHIAS MAYOR
09.00-09.30	Mobile phone radiofrequent electromagnetic fields (EMF) – biologic mechanism associated risks, preventive strategies Prof. Wilhelm Mosgoeller, Wien (A)	
09.30-10.00	Impact of electromagnetic handy radiation on gonads – Evidence based Prof. Michael von Wolff, Bern 15 minutes presentation, followed by a discussion with Prof. Wilhelm Mosgoeller at the audience	
10.00-10.30	Chances and risks of the new Swiss Reproductive Medicine law Prof. Christian De Geyter, Basel	
10.30-11.00	Coffee break & visit of the exhibition	EXHIBITION AREA
11.00-12.30	PLENARY 2 HEALTHY AGING – THE CHALLENGE Chairs: Prof. Petra Stute, Bern; PD Dr. Dorothea Wunder, Lausanne	MATHIAS MAYOR
11.00-11.25	Age-related changes of metabolism and musculoskeletal system Prof. Heike A. Bischoff-Ferrari, Zürich	
11.25-11.50	Age-related changes in cognition Prof. René Muri, Bern	
11.50-12.15	Age-related changes in female and male sexual function Dr. Sandra Fornage, Lausanne	
12.15-12.30	Discussion	
12.30-13.30	Lunch & visit of the exhibition	EXHIBITION AREA
13.30-14.00	KEYNOTE LECTURE Chair: Dr. Nicolas Vulliemoz, Lausanne The feasibility and associated risks of germline editing Dr. Ben Davies, Oxford (GB)	MATHIAS MAYOR

Thursday, January 16, 2020

14.00-15.30	PLENARY 3 CONTRACEPTIVE NEEDS: A DIFFERENT APPROACH <i>Chairs: Dr. Saira-Christine Renteria, Lausanne; Dr. Ruth Draths, Sursee</i>	MATHIAS MAYOR
14.00-14.25	I did everything right, so why am I pregnant? Dr. Françoise Livio, Lausanne	
14.25-14.50	Why Millenials need more than contraception? Dr. Anne-Emmanuelle Ambresin, Lausanne	
14.50-15.15	Is modern contraception effective enough for overweight women? Prof. Brigitte Leeners, Zürich	
15.15-15.30	Discussion	
15.30-16.00	Coffee break & visit of the exhibition	EXHIBITION AREA
16.00-17.30	PLENARY 4 HEALTHY AGING – THE SOLUTION <i>Chairs: Dr. Anna Raggi, Fertsuisse Basel and Olten; Dr. Maki Kashiwagi, Uster</i>	MATHIAS MAYOR
16.00-16.10	SMS Science Prize award	
16.10-16.35	Understanding and managing menopause-related changes in musculoskeletal metabolism and hormones Prof. Vanadin Seifert-Klauss, München (D)	
16.35-17.00	Managing age-related changes in cognition with hormones & beyond Prof. Cordian Beyer, Aachen (D)	
17.00-17.25	Managing age-related changes in female and male sexual function with hormones & beyond PD Dr. Gideon Sartorius, Basel; Dr. Simone Göttler, Basel	
17.25-17.30	Discussion	
17.30	Closing remarks & end of congress Dr. Nicolas Vulliemoz, Lausanne	MATHIAS MAYOR

Dr. Anne-Emmanuelle AMBRESIN	Lausanne
Prof. Cordian BEYER	Aachen (D)
Prof. Heike A. BISCHOFF-FERRARI	Zürich
Mrs Fabienne COQUILLAT	Lausanne
Dr. Ben DAVIES	Oxford (GB)
Prof. Christian DE GEYTER	Basel
Dr. Ruth DRATHS	Sursee
Mrs Véronique ECKERT	Sion
Dr. Sandra FORNAGE	Lausanne
Dr. Simone GÖTTLER	Basel
Dr. Maki KASHIWAGI	Uster
Prof. Brigitte LEENERS	Zürich
Dr. Françoise LIVIO	Lausanne
Prof. Wilhelm MOSGOELLER	Wien (A)
Prof. René MÜRI	Bern
Dr. Anna RAGGI	Basel/Olten
Dr. Saira-Christine RENTERIA	Lausanne
PD Dr. Gideon SARTORIUS	Basel
Prof. Vanadin SEIFFERT-KLAUS	München (D)
Prof. Petra STUTE	Bern
Prof. Michael VON WOLFF	Bern
Dr. Nicolas VULLIEMOZ	Lausanne
PD Dr. Dorothea WUNDER	Lausanne



Institut Biochimique SA

